Metabolic syndrome and prostate cancer: a review

Clin Oncol (R Coll Radiol). 2009 Apr;21(3):183-91. doi: 10.1016/j.clon.2008.11.013. Epub 2008 Dec 25.


Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Male
  • Metabolic Syndrome / etiology*
  • Orchiectomy / adverse effects
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / therapy*


  • Androgen Antagonists
  • Gonadotropin-Releasing Hormone